Phase III trial involved 594 patients across 20 countries Ceralasertib-Imfinzi combo showed no new safety concerns AstraZeneca shares fall 1% after trial results Dec 22 (Reuters) - AstraZeneca (AZN.L) ...
This guide was reviewed by a Business News Daily editor to ensure it provides comprehensive and accurate information to aid your buying decision. At least one of your employees is bound to lose their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback